Consequently, hindering NF-κB by controlling upstream regulatory molecules such as RIP1 and TRAF2 might be a more efficient and less cytotoxic approach in comparison to Bortezomib for the treatment of blood diseases. Here, NFKB1 is linked to blood disease.